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Following inducible expression in HEK293 cells the human orexin-1 receptor was 
targeted to the cell surface but became internalized following exposure to the peptide 
agonist orexin A. By contrast, constitutive expression of the human cannabinoid CB1 
receptor resulted in a predominantly punctate, intracellular distribution pattern 
consistent with spontaneous, agonist-independent internalization. Expression of the 
orexin-1 receptor in the presence of the CB1 receptor resulted in both receptors 
displaying the spontaneous internalization phenotype. Single cell fluorescence resonance 
energy transfer imaging indicated the two receptors were present as hetero-
dimers/oligomers in intracellular vesicles. Addition of the CB1 receptor antagonist SR-
141716A to cells expressing only the CB1 receptor resulted in re-localization of the 
receptor to the cell surface. Although SR-141716A has no significant affinity for the 
orexin-1 receptor, in cells co-expressing the CB1 receptor, the orexin-1 receptor was 
also re-localized to the cell surface by treatment with SR-141716A. Treatment of cells 
co-expressing the orexin-1 and CB1 receptors with the orexin-1 receptor antagonist SB-
674042 also resulted in re-localization of both receptors to the cell surface. Treatment 
with SR-141716A resulted in decreased potency of orexin-A to activate the MAP kinases 
ERK1/2 only in cells co-expressing the two receptors. Treatment with SB-674042 also 
reduced the potency of a CB1 receptor agonist to phosphorylate ERK1/2 only when the 
two receptors were co-expressed. These studies introduce an entirely novel 
pharmacological paradigm, whereby ligands modulate the function of receptors for 
which they have no significant inherent affinity by acting as regulators of receptor 
hetero-dimers.  
Abbreviations: eYFP, enhanced yellow fluorescent protein; GPCR, G protein-coupled 
receptor; Image-iTTM, WGA-Alexa Fluor594 plasma membrane marker; ROI, region of 
interest; SB-408124, (1-6,8-difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-
urea; SB-674042, (1-(5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-[(S)-2-(5-phentl-
[1,3,4]oxadiazol-2-ylmethyl)-pyrrolidin-1-yl)-methanone; SR-141716A, N-piperidinyl-5-(4-
chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide. WIN55, 221-2, (R)-
(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de-]-1,4-benzoxazin-6-yl]-
1-naphthalenylmethanone mesylate.  
Until recently it was widely believed that G protein-coupled receptors (GPCRs)1 existed and 
functioned as monomers and therefore that ligands with high pharmacological selectivity 
would be expected to target a single receptor. However, in recent years data employing a 
wide range of approaches have indicated that most GPCRs exist as dimers or, potentially, as 
high-order oligomers (1-4) although there may be exceptions (5). Apart from providing an 
explanation for observations such as co-operativity in the binding of agonist ligands (5-9), 
homo-dimerization between two copies of the same GPCR has somewhat limited 
implications for either novel drug design or the function of previously well characterized 
GPCR ligands. However, GPCRs represent the largest family of transmembrane receptors in 
the human genome and some 400 genes encode GPCRs that are believed to respond to 
endogenously produced ligands (10). Greater than 90% of these GPCRs are expressed to 
some extent in the central nervous system (11) and it is believed that specific, key small 
nuclei and, indeed, even individual neurons may express a substantial number of distinct 
GPCRs (11). Although largely studied in detail in heterologous expression systems, there is 
little doubt that certain pairs of GPCRs can form and exist as hetero-dimers (1-4). There is 
also an expanding literature about the existence of GPCR hetero-dimers in physiological 
settings (12-16) and these may exhibit quite distinct pharmacology and function from the 
corresponding homo-dimers. As such, GPCR hetero-dimers may offer entirely novel sets of 
potential therapeutic targets (17). This concept has recently been given a substantial boost by 
the identification of a non-peptide, agonist ligand that appears to have significant selectivity 
to active a k-opioid peptide receptor-δ-opioid peptide receptor hetero-dimer, both in 
heterologous expression systems and in vivo (16).  
GPCRs that respond to D9-tetrahydrocannabinol, the psychoactive principle of 
Cannabis, and a group of endogenously produced endo-cannabinoids, are termed CB1 and 
CB2 (18). The CB1 receptor is expressed predominantly in brain whilst the CB2 receptor is 
expressed largely in white cells of the immune system. The CB1 receptor is one of the most 
highly expressed GPCRs in both primate and rodent neurons and is widely expressed in 
neurons of the cortex, hippocampus, amygdala, basal ganglia and cerebellum (18-19). It has 
been appreciated for some time that the CB1 receptor can control conditioned drug-seeking 
(20-21) and antagonism of this receptor blocks the dopamine- releasing and motivational 
effects of nicotine (20-21). As such, a CB1 receptor antagonist/inverse agonist SR-141716A, 
also known as rimonabant, has been considered as a potential therapy in cessation of smoking 
programmes (22-24). Furthermore, as cannabinoid CB1 receptor agonists stimulate appetite, 
SR-141716A/rimonabant has also been assessed in weight reduction and anti-obesity 
programmes (25-26) and was recently approved for clinical use.  
The orexigenic peptides orexin A and orexin B were named for their ability to 
stimulate feeding responses and function via the G protein-coupled orexin-1 and orexin-2 
receptors (27). It has therefore been suggested that antagonists at one or either of these 
receptors might also be effective in weight loss programmes (28-29). The orexin-1 receptor is 
also widely expressed in brain (30-31), with distribution overlapping with the cannabinoid 
CB1 receptor in cerebral cortex, basal ganglia, thalamus and hippocampal formations as well 
as the lateral hypothalamus, a region of key importance in feeding and appetite control. The 
orexin system is also important in regulation of sleep, wakefulness and arousal (32) and low 
levels of orexin peptides are observed in some 90% of patients with sporadic narcolepsy-
cataplexy (33). Although syndromes associated with narcolepsy are more usually associated 
with effects at the orexin-2 receptor (34), alteration in levels of, or sensitivity to, the orexin 
peptides may generally provide links between wakefulness and feeding responses.  
Co-expression of the CB1 receptor and the orexin-1 receptor in CHO cells was 
recently reported to enhance the potency of orexin A to stimulate ERK MAP kinase 
phosphorylation, and this effect was blocked by addition of SR-141716A/rimonabant (35). 
Although Hilaret et al., (35) suggested that these two receptors might interact to produce this 
effect, this was not explored directly. In the current study we show that the human CB1 and 
orexin-1 receptors can indeed hetero-dimerize/oligomerize. Although the cellular trafficking 
and recycling characteristics of the two receptors are very different when expressed 
individually, when co-expressed and in the absence of receptor ligands, the phenotype of the 
CB1 receptor is dominant in the CB1-orexin-1 receptor hetero-dimer in that both receptors 
recycle spontaneously. Because of this, in cells containing the CB1 receptor-orexin-1 
receptor hetero-dimer, SR-141716A/rimonabant alters the cellular distribution not only of the 
CB1 receptor but also of the orexin-1 receptor although this ligand has no significant inherent 
affinity for the orexin-1 receptor. Moreover, in cells co-expressing the two receptors the 
orexin-1 antagonist SB-674042 (36) also alters the cellular distribution of the CB1 receptor, 
although this ligand has no inherent affinity for the CB1 receptor. Due to either their effects 
on receptor distribution or via direct allosteric modulation of the receptor hetero-dimer both 
SR-141716A and SB-674042 alter the effectiveness of agonists at the partner receptor. These 
studies introduce an entirely novel pharmacological paradigm, which may be significantly 
more widely applicable. We also speculate that this may contribute to the clinical effects of 
SR-141716A/rimonabant.  
Experimental Procedures  
Materials [3H]SR-141716A (50 Ci/mmol) was from Amersham Biosciences. [3H]SB-674042 
(36) was the kind gift of Dr. C. Langmead, GlaxoSmithKline, Harlow, Essex, U.K. All tissue 
culture materials were from Invitrogen (Paisley, Lanarkshire, U.K.). Oligonucleotides were 
purchased from ThermoElectron, Ulm, Germany. Orexin A was produced by 
GlaxoSmithKline. WIN55, 212-2 ((R)-(+)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de-]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone 
mesylate) was from Tocris Bioscience (Bristol, U.K.). The VSV-G antiserum was generated 
by Sigma Genosys. IMAGEiTTM was supplied by (Invitrogen, Paisley, U.K.). Antibodies 
recognizing ERK1/2 MAP kinases and their phosphorylated forms were from Cell Signaling 
(Hitchin, Herts., UK). Flp-In T-REx HEK293 cells were from Invitrogen. All other materials 
were supplied by Sigma (Gillingham, Dorset, UK).  
Molecular constructs- VSV-G-h-orexin-1-eYFP The VSV-G-human (h)-orexin-1-eYFP 
construct was created by splicing parts of two existing forms of the receptor (37). VSV-G-h-
orexin-1 receptor in pcDNA3 was digested with HindIII and AflII isolating the N-terminal 
portion of VSV-G-h-orexin-1 receptor. h-orexin-1 receptor-eYFP (also in pcDNA3) was 
digested with HindIII and AflII removing the N-terminal section of h-orexin-1 receptor. The 
isolated VSV-G-h-orexin-1 receptor N-terminal fragment was then subcloned into the HindIII 
and AflII sites of the digested h-orexin-1 receptor-eYFP construct. The resulting construct 
was digested with HindIII and XhoI to isolate VSV-G-h-orexin-1-eYFP that was then 
subcloned into pcDNA5/FRT/TO.  
CB1-receptor-CFP - The h-CB1 receptor in pcDNA3 was used as PCR template with the 
following primers.  
Sense primer:  
5'CCCAAGCTTATGAAGTCGATCCTAGATGGCCTT3'  
Anti-sense primer:  
5'CGGGGTACCCAGAGCCTCGGCAGACGT3'  
A HindIII site present in the sense primer and a KpnI site present in the anti-sense 
primer are underlined and the amplified fragment was digested and ligated into 
pcDNA3 upstream and in frame with CFP ligated between KpnI and NotI.  
Generation of stable Flp-In T-REx HEK293 cells - Cells were maintained in Dulbeccos' 
modification of Eagles' medium without sodium pyruvate, 4500 mg/L glucose and L-
glutamine, supplemented with 10% (v/v) foetal calf serum, 1% antibiotic mixture and 
10 mg/ml blastacidin at 37oC in a humidified atmosphere of air/CO2 (19:1). To generate 
Flp-In T-REx HEK293 cells (35-36) able to inducibly express VSV-G-h-orexin-1-eYFP, 
cells were transfected with a mixture containing the VSV-G-h-orexin-1-eYFP cDNA in 
pcDNA5/FRT/TO vector and the pOG44 vector (1:9) using lipofectAMINE (Invitrogen), 
according to the manufacturers' instructions. After 48 h, the medium was changed to 
medium supplemented with 200 mg/ml hygromycin B to initiate selection of stably 
transfected cells. To constitutively co-express a variant of the h-CB1 receptor in the 
inducible cell lines, the inducible VSV-G-h-orexin-1-eYFP expressing cell line was 
transfected with the appropriate cDNA construct as described above and resistant cells 
selected in the presence of 1 mg/ml G418. Resistant clones were screened for receptor 
expression by monitoring specific binding of [3H]SR-141716A in cell homogenates for 
the untagged h-CB1 receptor and by fluorescent microscopy for the h-CB1-CFP 
receptor. Cells were treated with 1 mg/ml doxycycline 24-96 h prior to assays to induce 
expression of the VSV-G-h-orexin-1-eYFP cloned into the Flp-In locus.  
Cell surface expression of VSV-G-h-orexin-1-eYFP Monolayers of cells in 96-well plates 
were induced with 1 mg/ml doxycycline for varying times. Afterwards cell surface 
receptors were labelled with anti-VSV-G antibody (1:1000) in growth medium for 30 
min at 37oC. The cells were washed once with 20 mM Hepes/Dulbeccos' modified 
Eagles' medium and then incubated for another 30 min at 37oC in growth medium 
supplemented with horseradish-peroxidase-conjugated anti-rabbit IgG as secondary 
antibody and 1 mM Hoechst nuclear stain (Sigma) to determine cell number. The cells 
were then washed twice with phosphate buffered saline and incubated with SureBlue 
(Insight Biotechnology) for 5 min in the dark at room temperature and the absorbance 
read at 620 nm in a Victor2 plate reader (Packard Bioscience).  
Immunoblot detection of VSV-G-h-orexin-1-eYFP Cells were grown in 12-well plates and 
receptor expression induced with 1 mg/ml doxycycline for varying times. Cells were 
then place on ice, washed twice with cold phosphate buffered saline and lysed in RIPA 
buffer. After 1 h at 4oC, the lysates were centrifuged for 10 min at 20,800 x g at 4oC to 
remove insoluble material. The samples were mixed with 5 x reducing loading buffer 
and heated for 3 min at 95oC. Cell lysates were resolved using SDS-PAGE gel 
electrophoresis. VSV-G-h-orexin-1-eYFP expression was detected by protein 
immunoblotting using anti-VSV-G antibody and horseradish-peroxidase-conjugated 
anti-rabbit IgG as secondary antibody for immunodetection.  
ERK1/2 phosphorylation and immunoblots  
Cells were grown in 12-well plates and serum starved overnight prior to treatment with 
ligands as indicated. Cell lysates were prepared as above. ERK1/2 phosphorylation was 
detected by protein immunoblotting using phospho-specific antibodies and horseradish-
peroxidase-conjugated anti-rabbit IgG as secondary for immunodetection. After 
visualizing ERK1/2 phosphorylation, the PVDF membranes were stripped and re-
probed using a total anti-ERK1/2 antibody.  
Pharmacological redistribution assays using receptor inverse agonists/antagonists Cells 
were grown in 12-well plates and receptor expression induced with 1 mg/ml doxycycline 
for 72 h. Following this cells were incubated for 15 min at 4oC in Earle's buffer (140 
mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.9 mM MgCl2-6H2O, 25 mM HEPES, pH 7.6) 
supplemented with 0.2 % bovine serum albumin and 0.01 % glucose. Cells were then 
incubated in supplemented Earle's buffer containing either 1 ¼M SR-141716A or 5 ¼M 
SB674042 for 30 min at 4oC, before being incubated at 37oC for 3 h prior to either 
imaging by epifluorescence microscopy or used in the ERK1/2 phosphorylation assays.  
Cell membrane preparation Pellets of cells were resuspended in 10mM Tris, 0.1mM EDTA, 
pH 7.4 (TE buffer) and the cells homogenized using 40 strokes of a glass on Teflon 
homogenizer. Samples were centrifuged at 1000 x g for 10 min at 4oC to remove unbroken 
cells and nuclei. The supernatant fraction was removed and passed through a 25 gauge needle 
10 times before being transferred to ultra-centrifuge tubes and subjected to centrifugation at 
50,000 x g for 30 min. The supernatant was discarded and the pellet resuspended in TE 
buffer. Protein concentration was assessed, membranes diluted to 1mg/ml and stored at -80oC 
until required.  
Radioligand binding - [3H]SR-141716A binding Reaction mixtures were established in a 
volume of 1000 ml containing 20-60 mg of membrane protein in binding buffer (50 mM Tris, 
1 mM EDTA, 3 mM MgCl2 and 0.3% BSA, pH 7.4) containing a range of concentrations 
(0.25 - 8 nM) of [3H]SR-141716A. Potential competing ligands (orexin A, 0.5 mM or SB-
674042 5 mM) were diluted in binding buffer. Non-specific binding was determined using 
cold SR-141716A (2 mM). Samples were incubated for 90 min at 37oC prior to filtration 
through Whatman GF/C filters. Data was analysed using Graphpad Prism, and BMAX and Kd 
values determined via saturation binding analysis.  
[3H]SB-674042 binding Reaction mixtures were established in a volume of 500ml 
containing 5mg of membrane protein in binding buffer (25 mM HEPES, 0.5 mM 
EDTA, 2.5 mM MgCl2, 0.5% BSA and 0.025% bacitracin, pH 7.4) supplemented with 5 
nM [3H]SB-674042 (36). Non-specific binding was determined using SB-408124 (1-6,8-
difluoro-2-methyl-quinolin-4-yl)-3-(4-dimethylamino-phenyl)-urea (3¼M). Samples 
were incubated for 60 min at 25oC prior to filtration through Whatman GF/C filters  
Confocal laser scanning microscopy  
Cells were imaged using a Zeiss LSM 5 Pascal laser scanning confocal microscope (Carl 
Zeiss Inc., Thornwood, NY) equipped with a 63 x oil-immersion Plan Fluor Apochromat 
objective lens with a numerical aperture of 1.4. A pinhole of 20 and an electronic zoom of 1 
or 2.5 was used. The excitation laser line for eYFP was the 514nm argon laser with detection 
via a 475-525nm band pass filter. The excitation laser line for CFP was the 458nm argon 
laser with detection via a 505-530nm band pass filter. Cells grown on coverslips were washed 
3 times with ice-cold PBS. For internalization studies cells were pre-treated with specific 
antagonist or control for 30 min at 37oC, the agonist was then added to these cells for further 
30 min at 37oC. Cells were fixed for 10 min at room temperature using 4% paraformaldehyde 
in PBS/5% sucrose. The cells were washed a further 3 times in ice-cold PBS prior to being 
mounted onto microscope slides with 40% glycerol in PBS. The images were analyzed with 
Metamorph software, (version 6.3.3; Molecular Devices Corp., Downing, PA).  
Epifluorescence microscopy - Dual imaging -h-CB1-CFP and VSV-G-h-orexin-1-eYFP 
receptor fusions  
Paraformaldehyde fixed cells, expressing the appropriate receptor fusion protein were imaged 
in 2D or 3D using an inverted Nikon TE2000-E microscope (Nikon Instruments, Melville, 
NY) equipped with a x60, (NA=1.4), oil-immersion Plan Fluor Apochromat lens, a z-axis 
linear encoder and a cooled digital Cool Snap-HQ CCD camera (Roper 
Scientific/Photometrics, Tucson, AZ).  
Epifluorescence excitation light was generated by an ultra high point intensity 75 W xenon 
arc Optosource lamp (Cairn Research, Faversham, Kent, UK) coupled to a computer 
controlled Optoscan monochromator (Cairn Research, Faversham, Kent, UK). 
Monochromator was set to 436/12 nm and 500/5 nm for the sequential excitation of CFP and 
eYFP respectively. CFP and eYFP excitation light was transmitted through the objective lens 
using the following single pass dichroics: 455DCLP for CFP and Q515LP for eYFP. CFP and 
eYFP fluorescence emission was controlled via a high speed filterwheel device (Prior 
Instruments) containing the following emitters: HQ480/40 nm for CFP; HQ535/30 nm for 
eYFP. Using these filter sets, the fluorophores were easily separated with no bleed through.  
Images were collected using a Cool Snap-HQ digital camera operated in 12-bit mode. 
Computer control of all electronic hardware and camera acquisition was achieved using 
Metamorph software (version 6.3.3; Molecular Devices Corp., Downing, PA).  
For 3D imaging, stacks of images, (2 x 2 binning, 200-300 msec exposure/image), with a 
0.26-µm Z step (~20-25 frames/stack) were sequentially acquired for each GFP variant.  
VSV-G-h-orexin-1-eYFP receptor fusion and wheatgerm agglutinin-Alexa Fluor 594 
fluorescent-labelled plasma membrane marker To fluorescently visualize the plasma 
membrane in live cells expressing the VSV-G-h-orexin-1-eYFP receptor construct cells were 
treated, (as specified by the manufacturer), with the reagents in the Image-iT plasma 
membrane and nuclear labeling kit (Invitrogen), in which the plasma membrane is 
specifically labeled with wheatgerm agglutinin (WGA)-Alexa Fluor 594 and nuclei are 
stained simultaneously with Hoechst 33342. eYFP was excited as previously described and 
Alexa Fluor 594 was excited at 575/12nm and imaged using the following filter set, 
(dichroic: Q595LP; emitter:HQ645/75 nm). Using these filters, no bleed through was 
observed. Sequential 12 bit images were collected as previously outlined above.  
FRET imaging Cells were grown on poly-D-lysine treated coverslips and transiently 
transfected with appropriate CFP/eYFP constructs. Coverslips were placed into a microscope 
chamber containing physiological saline solution (130 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 
mM MgCl2, 20 mM HEPES, 1 0mM D-glucose, pH 7.4). Using an Optoscan 
monochromator, the CFP and eYFP fluorophores were excited sequentially at 500/5 and 
430/12 nm respectively. Images were obtained individually for CFP, eYFP, and CFP-eYFP 
FRET filter channels using the appropriate excitation wavelength, a dual dichroic mirror, 
(86002v2bs; Chroma Inc., Rockingham, VT) and a high speed filterwheel device (Prior 
Instruments) containing the following band pass emitters: HQ470/30 nm for CFP; 
HQ535/30nm for eYFP. The illumination time was 250 ms and binning was set to 2x2. 
Metamorph imaging software, (version 6.3.3; Molecular Devices Corp., Downing, PA), was 
used to quantify the FRET images using the sensitized FRET method. Corrected FRET 
(FRETc) was calculated using a pixel-by-pixel methodology using the equation FRETc = 
FRET - (coefficient B x CFP) - (coefficient A x eYFP), where CFP, eYFP and FRET values 
correspond to background corrected images obtained through the CFP, eYFP and FRET 
channels. B and A correspond to the values obtained for the CFP (donor) and eYFP 
(acceptor) bleed-through co-efficients respectively, calculated using cells singly transfected 
with either the CFP or eYFP protein alone. To correct the FRET levels for the varying 
amounts of donor (CFP) and acceptor (YFP), normalized FRET was calculated using the 
equation FRETn = FRETc / CFP, where FRETc and CFP are equal to the fluorescence values 
obtained from single cells.  
Image analysis - Co-localization - h-CB1-CFP and VSV-G-h-orexin-1-eYFP receptor 
constructs For the analysis of h-CB1-CFP and VSV-G-h-orexin-1-eYFP receptor constructs, 
a region of no fluorescence adjacent to the cell was used to determine the background level of 
fluorescence in the CFP and eYFP channels. The background amount was then subtracted 
from each pixel in each channel. Correlation coefficients were measured by comparing the 
amounts of fluorescence measured in each matched pixel of the two different channels using 
the Metamorph “correlation plot” application. The degree of co-localization was quantified 
by plotting the amount of background-subtracted yellow eYFP fluorescence from the pixels 
against the amount of back-ground cyan fluorescence in the corresponding pixels of the eYFP 
image. Correlation coefficients were quantified that described the degree by which CFP and 
eYFP fluorescence at each pixel within the region varied from a perfect correlation of 1.00.  
VSV-G-h-orexin-1-eYFP receptor and plasma membrane Correlation coefficients were 
quantified by manually drawing a rectangular region of interest (ROI) on the WGA-Alexa 
Fluor 594 labelled plasma membrane. The ROI was then selected and transferred to the 
matched image acquired in the eYFP channel. Using the Metamorph “correlation plot” 
module, correlation coefficients were quantified that described the degree by which WGA-
Alexa Fluor 594 and eYFP fluorescence at each pixel within the rectangular region varied 
from a perfect correlation of 1.00.  
Quantification of surface versus intracellular receptors Fluorescent microscopy was used for 
measurement of surface expressed and intracellular receptors. To quantitatively measure the 
total h-CB1-CFP and VSV-G-h-orexin-1-eYFP receptor fluorescence intensity, images were 
deconvoluted using an iterative and constrained algorithm (Autodeblur software, version 
9.3.6, Autoquant Imaging, Watervliet, NY) to produce high resolution images that were used 
to identify groups of adjacent pixels or "segments" that corresponded to receptors located on 
the cell surface and intracellular vesicles. For images with good contrast and low noise, 
intensity thresholding is the standard method of segmentation, however, it is extremely 
difficult to obtain well segmented objects especially 2D objects that fork and merge. The 
object counting module of Autoquant imaging software offers a powerful manual 
segmentation paint brush tool that allows users to segment complex objects and easily 
distinguish between signals in the plasma membrane and in the cytoplasm, by defining a 
region of the raw image to be segmented using this tool. The paintbrush has varying 
diameters of 1, 3 or 5 pixels which the user can click to designate the region directly 
underneath the mouse pointer to be part of the threshold region or can click and drag to 
“paint” the region. As the mouse is dragged the region underneath it becomes part of the 
segmented region. This region is then displayed as a yellow mask over the grayscale data. 
Once manual thresholding is completed a new image is created in which all pixels of the raw 
image that are not part of the segmentation mask are set to zero, or effectively removed.  
The manual segmentation method was used to quantify the mean total fluorescence intensity 
values corresponding to CFP or eYFP tagged receptors located at the membrane surface and 
cytoplasm of the cell was quantified using this method of manual segmentation. The total 
fluorescence pixel intensity measured from membrane and intracellular receptor segmented 
pixels was expressed as a percentage of the total fluorescent CFP or eYFP intensity. These 
values were exported into PRISM 4.03, (GraphPAD Software, San Diego, CA) and all data 
were expressed as the mean +/- S.E.M. The number of cells analysed from each experimental 
group was 6 and the statistical significance of any difference between mean values was 
determined using a Student's t test.  
RESULTS  
The human (h)-orexin-1 receptor (37) was modified at the N-terminus to introduce the 
VSV-G epitope tag and at the C-terminus by in-frame addition of enhanced yellow 
fluorescent protein (eYFP) to generate VSV-G-h-orexin-1-eYFP. A cDNA able to encode 
this modified construct was cloned into the Flp-In locus of HEK293 Flp-In T-REx cells to 
allow inducible expression under the control of the tetracycline/doxycycline-on promoter (38-
39). Expression of VSV-G-h-orexin-1-eYFP in various clones of these cells was entirely 
dependent upon addition of doxycycline (Figure 1 and data not shown). As monitored by 
confocal microscopy, following treatment with doxycycline (1 mg/ml, 72 h) eYFP 
fluorescence appeared to be located predominantly at the cell surface (Figure 1a). This was 
confirmed by co-staining of the cells with the WGA-Alexa Fluor594 plasma membrane 
marker, Image-iTTM. As shown in Figure 1b pixel by pixel analysis of a defined region of 
interest (ROI) resulted in a very high overlap correlation co-efficient (r2 = 0.92). Quantitative 
pixel by pixel analysis of the distribution of cell surface versus intracellular eYFP 
fluorescence demonstrated 88.6 +/-3.6 % of the receptor to be at the cell surface 72 h after 
induction of VSV-G-h-orexin-1-eYFP expression (Table 1), a proportion that was unaffected 
by maintenance of the presence of doxycycline for different times (data not shown). As the 
N-terminus of GPCRs is anticipated to be extracellular, intact cell anti-VSV-G ELISA assays 
(Figure 1c) confirmed delivery of the construct to the cell surface and appropriate integration 
of the construct into and across the plasma membrane. Time-courses of doxycycline 
treatment indicated that expression of VSV-G-h-orexin-1-eYFP could be detected 
immunologically within 12-18 h, increased up to 48 h and was maintained for at least 96 h 
(Figure 1d).  
The expressed VSV-G-h-orexin-1-eYFP construct was functional but displayed no 
obvious constitutive activity because both induction of expression and addition of the peptide 
agonist orexin A were required to cause phosphorylation of the MAP kinases ERK1 and 
ERK2 (Figures 2a, b). As anticipated from previous work (37), the maintained presence of 
the peptide agonist orexin A (0.5 mM, 30 min) resulted in substantial internalization of VSV-
G-h-orexin-1-eYFP (Figure 2c), a process also shown previously (37) to be b-arrestin and 
clathrin-dependent. This was blocked by prior addition of the orexin-1 receptor antagonist 
SB-674042 (33) (Figure 2d) that had no detectable direct effect on the distribution of VSV-
G-h-orexin-1-eYFP (Figure 2d).  
The cells described above were further transfected with a cDNA encoding the human 
cannabinoid CB1 (h-CB1) receptor to cause stable, constitutive expression of this polypeptide 
and individual clones isolated. When VSV-G-h-orexin-1-eYFP expression was induced in 
these cells by addition of doxycycline the distribution of VSV-G-h-orexin-1-eYFP was now 
markedly different than in the absence of h-CB1 receptor expression (Figure 3a). 
Substantially less (61.3 +/- 2.9 %) of the eYFP was present at the cell surface 24 h after 
induction of VSV-G-h-orexin-1-eYFP and this was further reduced (to 47.2 +/- 2.6 %) 72 h 
after induction of expression (Table 1). Now the majority of the signal was present in 
punctate, intracellular vesicles with a pattern resembling that generated following addition of 
orexin A to cells expressing only the VSV-G-h-orexin-1-eYFP construct (compare Figure 
2c). Ligand binding studies employing [3H]SR-141716A/rimonabant (Figure 3b) confirmed 
a lack of specific cannabinoid CB1 receptor binding sites in both parental HEK293 Flp-In T-
REx cells and in those inducibly expressing only VSV-G-h-orexin-1-eYFP but demonstrated 
2.8 +/- 0.11 pmol binding sites/mg membrane protein in clone 16 of the cells constitutively 
expressing h-CB1 receptor without induction of VSV-G-h-orexin-1-eYFP (Table 2). This 
level of expression was unaffected by induction of VSV-G-h-orexin-1-eYFP expression (3.0 
+/- 0.06 pmol/mg membrane protein) as was the Kd for [3H]SR-141716A (Table 2).  
Because the h-CB1 receptor in these cells was unmodified and therefore could not be 
observed directly we generated further cell lines in which the h-CB1 receptor with cyan 
fluorescent protein fused in frame to the receptor C-terminal tail (h-CB1-CFP) was expressed 
constitutively and where VSV-G-h-orexin-1-eYFP expression could be induced. In these 
cells, in the absence of VSV-G-h-orexin-1-eYFP expression, the pattern of h-CB1-CFP 
distribution was largely intracellular, 91.2 +/- 2.0%, (Table 3) and concentrated in punctuate 
vesicles (Figure 4a (ii)). [3H]SR-141716A binding studies on cell membrane preparations 
indicated expression of 1.62 +/- 0.08 pmol/mg membrane protein (Table 2). Induction of 
expression of VSV-G-h-orexin-1-eYFP in these cells did not alter h-CB1-CFP expression 
levels, affinity to bind [3H]SR-141716A (Table 2), or the pattern of h-CB1-CFP distribution 
(Figure 4a (v), Table 3). However, unlike in the absence of h-CB1 receptor, much (66.1 +/- 
3.1 %) of the expressed VSV-G-h-orexin-1-eYFP now displayed a punctate, intracellular 
pattern of distribution (Figure 4a (iv), Table 3) and merging of the signals corresponding to 
VSV-G-h-orexin-1-eYFP and h-CB1-CFP indicated marked overlap of distribution and 
potential co-localization (Figure 4a (vi)). Detailed pixel by pixel analysis of the patterns of 
distribution of the two receptors in individual cells demonstrated a very high intracellular 
overlap correlation coefficient (r2 = 0.87) (Figure 4b). As the effect of h-CB1-CFP 
expression on the distribution of VSV-G-h-orexin-1-eYFP was entirely ligand-independent 
this was suggestive of direct protein-protein interaction and hence hetero-
dimerization/oligomerization between the two GPCRs. To test this directly we performed 
single cell fluorescence resonance energy transfer (FRET) imaging studies (40-41) on cells 
expressing either h-CB1-CFP or VSV-G-h-orexin-1-eYFP alone or co-expressing these two 
constructs. Substantial FRET signals were obtained from intracellular sites of these cells only 
following co-expression of both receptor constructs (Figure 4c), consistent with direct h-CB1 
receptor-h-orexin-1 receptor interactions in such vesicles.  
The effect of the h-CB1 receptor on the cellular distribution of the orexin-1 receptor 
was not a general, non-specific effect. We generated further HEK293 Flp-In T-REx cell lines 
in which a h-m-opioid receptor C-terminally tagged with eYFP was expressed stably and 
constitutively and in which h-CB1-CFP expression could be induced by addition of 
doxycycline. In these cells, h-m-opioid receptor-eYFP was located largely at the cell surface 
both in the absence and presence of h-CB1-CFP expression whilst, as anticipated from the 
foregoing, following induction of expression, h-CB1-CFP was present predominantly in 
punctuate intracellular vesicles (Figure 5).  
[3H]SR-141716A binding was specific for the h-CB1 receptor. Neither the peptide 
orexin A nor the selective non-peptide orexin-1 receptor antagonist SB-674042 displayed any 
significant ability to compete for h-CB1 receptor binding (Figure 6a). Equally, SR-
141716A/rimonabant had no significant affinity for the orexin-1 receptor. Pre-treatment of 
cells expressing only VSV-G-h-orexin-1-eYFP with SR-141716A/rimonabant was unable to 
prevent orexin A-mediated internalization of VSV-G-h-orexin-1-eYFP (Figure 6b) and SR-
141716A/rimonabant had no direct effect on the cellular distribution of VSV-G-h-orexin-1-
eYFP (Figure 6b). Furthermore, SR-141716A/rimonabant was unable to compete with 
[3H]SB-674042 in ligand binding studies in membranes of cells induced to express VSV-G-h-
orexin-1-eYFP (Figure 6c).  
In cells expressing only h-CB1-CFP sustained treatment with SR-
141716A/rimonabant (1 mM, 3 h) resulted in a substantial re-distribution of the h-CB1-CFP 
receptor to the cell surface (Figure 7, Table 3). In contrast, and as expected, treatment of 
cells expressing only h-CB1-CFP with SB-674042 (5 mM, 3 h) was without effect on the 
distribution of h-CB1-CFP (Figure 7, Table 3). In cells induced to express VSV-G-h-orexin-
1-eYFP in the presence of constitutive expression of h-CB1-CFP, SR-141716A/rimonabant 
treatment re-distributed substantial fractions of both h-CB1-CFP and VSV-G-h-orexin-1-
eYFP to the cell surface (Figure 8a, Table 3). As well as being able to block orexin-A 
mediated internalization of VSV-G-h-orexin-1-eYFP, sustained treatment of cells co-
expressing VSV-G-h-orexin-1-eYFP and h-CB1-CFP with SB-674042 (5 mM, 3 h) resulted 
in re-distribution of VSV-G-h-orexin-1-eYFP from punctate intracellular vesicles back to the 
cell surface and also resulted in significant cell surface accumulation of h-CB1-CFP (Figure 
8a, Table 3). Furthermore, FRET imaging studies on cells co-expressing h-CB1-CFP and 
VSV-G-h-orexin-1-eYFP and treated with SR-141716A/rimonabant (1mM, 3h) allowed 
detection of protein-protein interactions involving these two GPCRs at the surface of 
individual cells (Figure 8b) whereas no significant FRET signals were obtained in cells 
treated with SR-141716A/rimonabant when either receptor construct was expressed 
individually (Figure 8b).  
Orexin A stimulated phosphorylation of the ERK1 and ERK2 MAP kinases in a 
concentration-dependent manner in all the cell lines in which VSV-G-h-orexin-1-eYFP 
expression was induced (Figure 9) but, as noted earlier (Figure 2a), this was not observed 
without induction of h-orexin-1 receptor expression. As anticipated, based on the lack of 
affinity of SR-141716A/rimonabant for the orexin-1 receptor (Figure 6), treatment of cells 
expressing only VSV-G-h-orexin-1-eYFP with SR141716A/rimonabant (1 mM, 3 h) did not 
alter the potency of orexin A to cause phosphorylation of the ERK MAP kinases (Table 4). 
However, in cells induced to co-express VSV-G-h-orexin-1-eYFP and h-CB1-CFP, SR-
141716A/rimonabant pre-treatment substantially reduced the potency of orexin A (Figure 9, 
Table 4), consistent with binding of SR-141716A/rimonabant to the VSV-G-h-orexin-1-
eYFP- h-CB1-CFP hetero-dimer altering signalling sensitivity via the partner polypeptide. 
Without SR-141716A/rimonabant pre-treatment, co-expression of VSV-G-h-orexin-1-eYFP 
and h-CB1-CFP resulted in a small, but statistically significant, increase in the potency of 
orexin A to stimulate ERK1 and ERK2 MAP kinase phosphorylation (Table 4). Pre-
treatment with SB-674042 (5 mM, 3 h), which has no significant affinity at the h-CB1 
receptor (Figure 6), was without effect on the potency of the CB1 receptor agonist WIN55, 
212-2 to stimulate phosphorylation of the ERK MAP kinases in cells expressing only h-CB1-
CFP (Table 5). However, in cells induced to express VSV-G-h-orexin-1-eYFP in the 
presence of h-CB1-CFP pre-treatment with SB-674042 resulted in a 2 fold reduction in 
potency of WIN55, 212-2 to stimulate ERK1 and ERK2 MAP kinase phosphorylation (Table 
5).  
Levels of VSV-G-h-orexin-1-eYFP expression in HEK293 Flp-In T-REx cells 
constitutively expressing h-CB1-CFP could be modulated by altering the concentration of 
doxycycline used as inducer. This allowed us to explore the effect of differing levels of VSV-
G-h-orexin-1-eYFP on ERK MAP kinase phosphorylation and effects of SR-
141716A/rimonabant on this (Table 6). Induction of VSV-G-h-orexin-1-eYFP by treatment 
with low concentrations of doxycycline (0.025 or 0.1 ng/ml) reduced expression levels of 
VSV-G-h-orexin-1-eYFP to respectively 1 and 2.5% of that produced by treatment with 1 
mg/ml doxycycline. Interestingly, following induction of lower levels of VSV-G-h-orexin-1-
eYFP by treatment of the cells with 0.1 ng/ml doxycycline, the fraction of VSV-G-h-orexin-
1-eYFP at the cell surface at steady-state was markedly lower (8.1 +/- 1.1 %) than when 
higher levels of the receptor were induced by treatment with 1 mg/ml doxycycline (33.9 +/- 
3.1 %), whilst the distribution of h-CB1-CFP between cell surface and intracellular vesicles 
was unaltered. These data suggest that with low level expression, most of the VSV-G-h-
orexin-1-eYFP was within a recycling hetero-dimeric/oligomeric complex with h-CB1-CFP. 
In cells lacking h-CB1-CFP expression, lower levels of VSV-G-h-orexin-1-eYFP reduced the 
potency of orexin A to stimulate ERK MAP kinase phosphorylation (Table 6) as expected 
from basic pharmacological principles. However, as observed with higher level VSV-G-h-
orexin-1-eYFP expression, even with these lower levels of orexin-1 receptor expression, in 
the presence of h-CB1-CFP the potency of orexin A was always greater than in the absence 
of the CB1 receptor (Table 6) and, in all cases, this was reduced by pre-treatment with SR-
141716A/rimonabant (Table 6).  
DISCUSSION  
Recent years have seen great advances in understanding the significance of GPCR quaternary 
structure. Although considered to exist and function as monomers for many years, it is now 
well established that most (1-4), but perhaps not all (5), GPCRs exist as dimers and/or higher-
order oligomers and that such quaternary structure is required for plasma membrane delivery 
and function (42). As well as dimerization/oligomerization between monomers of the same 
GPCR, there has been growing evidence that at least certain pairs of co-expressed GPCRs 
have the potential to hetero-dimerize/oligomerize. Such interactions have been reported to 
modulate signal transduction cascades activated by the GPCRs (43), their pharmacology (44) 
and cellular trafficking (38, 45-46). Beyond the well established requirement for hetero-
dimerization between the GABABR1 and GABABR2 gene products to generate the functional 
GABAB receptor (47) and for hetero-dimerization between the T1R3 and either T1R1 or 
T1R2 receptors to generate respectively the umami and sweet taste receptors (48) there is 
growing interest in the concept that hetero-dimerization between co-expressed family A 
GPCRs is relevant to physiology and that such hetero-dimers might offer an entirely new 
portfolio of therapeutic targets to modulate disease (17). For this to be the case it is vital 
either that synthetic ligands can be identified that interact selectively with GPCR hetero-
dimer pairs or that it is demonstrated that ligands with well established pharmacology can be 
shown to regulate the activity or function of a GPCR within a hetero-dimer for which it has 
no inherent binding affinity. An example of a ligand with selective agonist action at a GPCR 
hetero-dimer appears to be 6'-guanidinonaltrindole as it is reported to display substantially 
higher potency and efficacy to generate signals in cells co-expressing the k-opioid peptide 
and δ-opioid peptide receptors than when either of these GPCRs is expressed alone (16). We 
now show that antagonists at the cannabinoid CB1 and the orexin-1 receptors regulate the 
cellular distribution of both receptors and functional potency of agonists of the other receptor 
when the two GPCRs are co-expressed, and that this is despite the fact these antagonists have 
no inherent affinity to bind the partner receptor when each is expressed in isolation.  
Particularly for the metabotropic glutamate-like, class C receptors, where chimeric 
receptors consisting of the extracellular ligand binding domain of one receptor and the seven 
transmembrane bundle and intracellular elements of a second can easily be produced, it is 
now clear that signal transduction subsequent to ligand binding can proceed via trans-
activation via the second transmembrane element of the dimer as well as via cis-activation 
(49). Similar data is beginning to emerge for dimers of the rhodopsin-like, class A GPCRs 
and this is consistent with observations of co-operativity in effects of ligand binding (7, 9, 
44). This is particularly relevant as interactions between pairs of GPCRs are expected to 
result in allosteric interactions between them, as recently observed following co-expression of 
the CCR2 and CCR5 chemokine receptors (50).  
Previous studies indicated that co-expression of the cannabinoid CB1 receptor and the 
orexin-1 receptor in CHO cells increases the potency of the orexigenic peptide orexin A to 
cause stimulation of the ERK1/2 MAP kinases and that this effect is blocked by short term 
treatment with SR-141716A or by treatment of the cells with pertussis toxin to prevent CB1 
receptor signalling (35). Both these observations are consistent with the concept that 
constitutive signalling from the CB1 receptor was responsible for this phenotype because SR-
141716A has been described as an `inverse agonist' at the CB1 receptor (35, 51). The current 
results are significantly different. We demonstrate that simple co-expression of these two 
receptors has a relatively small effect on the potency of orexin A to cause phosphorylation of 
the ERK1/2 MAP kinases. We do not, however, have an obvious, simple explanation of the 
differences in our data from those of Hilairet et al., (35). Certainly the experiments have been 
performed in different cell backgrounds and, perhaps more importantly, we observed that co-
expression of the human forms of these two receptors markedly alters the cellular distribution 
of the orexin-1 receptor. This is because, as noted previously by others in both HEK293 cells 
(52) and isolated neurons (53), the human CB1 receptor recycles constitutively and, whilst 
when expressed on its own, the orexin-1 receptor is maintained predominantly at the cell 
surface until stimulated by the agonist orexin A, in the presence of the CB1 receptor the 
orexin-1 receptor adopts the phenotype of the CB1 receptor because the two receptors form a 
hetero-dimer/oligomer in which the recycling phenotype of the CB1 receptor is dominant. 
Hilairet et al., (35) reported only cell surface localization of the CB1 receptor and no 
alteration of the distribution of the orexin-1 receptor in the presence of the CB1 receptor. 
Importantly, however, co-expression with the h-CB1 receptor does not result in an altered 
distribution phenotype for all GPCRs that might have been suggestive of a non-specific 
effect. When we generated further cell lines to allow expression of the h-m-opioid receptor, 
this was at the cell surface in the absence of h-CB1-CFP expression and remained at the cell 
surface with induction of h-CB1-CFP expression.  
Sustained treatment of cells expressing only the CB1 receptor with SR-
141716A/rimonabant trapped a substantial proportion of the CB1 receptor at the cell surface 
and, when the orexin-1 receptor was also expressed, SR-141716A/rimonabant treatment also 
moved this receptor to the cell surface. This is despite SR-141716A/rimonabant being unable 
to block orexin A-mediated internalization of the orexin-1 receptor and being unable to 
compete with [3H]SB-674042 to bind to the orexin-1 receptor. Likewise, treatment of cells 
expressing only the CB1 receptor with SB-674042 had no effect on cellular distribution of 
this receptor although this ligand caused re-distribution of the CB1 receptor to the cell surface 
when it was co-expressed with the orexin-1 receptor at which SB-674042 is an antagonist. In 
concert with single cell FRET imaging of interactions between CB1-CFP and orexin-1 
receptor-eYFP, which we were able to observe in intracellular vesicles in the absence of SR-
141716A/rimonabant and at the cell surface following treatment with this ligand, these 
pharmacological studies provide unambiguous identification of CB1 receptor-orexin-1 
receptor hetero-dimerization/oligomerization.  
These results may have important, more general implications than are currently 
appreciated for understanding the pharmacology and function of ligands. In ligand 
identification programmes in the pharmaceutical industry, interaction and/or functional 
screens are generally performed using cells or membranes of cells transfected to express a 
single molecular target of interest. Even in subsequent counter-screens to assess ligand 
selectivity for the target, potential interactions with related targets are usually assessed on a 
`one target at a time' basis. Using such approaches SR-141716A/rimonabant is clearly 
defined simply as a CB1 receptor selective antagonist/inverse agonist and SB-674042 as a 
selective orexin-1 receptor blocker. Indeed, as shown herein SR-141716A/rimonabant has no 
inherent affinity to bind directly to the orexin-1 receptor or SB-674042 to bind the CB1 
receptor. The distribution of these two GPCRs overlaps in the brain (18-19, 30-31) and 
although we show here that co-expressed orexin-1 and CB1 receptors form a hetero-
dimeric/oligomeric complex there remains no direct evidence that these two receptors do 
interact in vivo. Efforts to assess this are beyond the scope of the current studies but clearly 
will be an important next step. Because binding of SR-141716A/rimonabant or SB-674042 to 
such a hetero-dimer complex alters the cellular distribution of both receptors and the potency 
of agonists at each receptor to activate signalling, these observations may have implications 
for the in vivo action of `CB1 specific' antagonists including SR-141716A/rimonabant. 
Although SR-141716A/rimonabant is known to limit conditioned drug-seeking, and hence 
may well be useful as an anti-craving therapeutic, it is also known to produce weight loss via 
reduced food intake. Although both of these effects are consistent with reversing known 
effects of CB1 receptor stimulation, activation of the orexin-1 receptor is also a pro-feeding 
stimulus (54) and loss of weight and anorexia is associated with antagonists of this receptor 
(55). Because we demonstrate that treatment with SR-141716A/rimonabant, only of cells co-
expressing the CB1 and the orexin-1 receptor, results in decreased potency of orexigenic 
signalling through the orexin-1 receptor it is clearly an interesting concept that at least some 
of the clinical capacity of SR-141716A/rimonabant to decrease feeding and hence cause 
weight loss may reflect its interaction with CB1/orexin-1 receptor hetero-dimers. 
Interestingly, orexin-containing neurones are also associated with reward seeking and 
activation of this system re-instates extinguished drug-seeking behaviours, effects that are 
also blocked by an orexin-1 receptor antagonist (56-57). Given the efficacy of SR-
141716A/rimonabant as an anti-craving agent, an intriguing speculation is that part of this 
effect may also reflect binding to cannabinoid CB1/orexin-1 receptor hetero-dimers in vivo.  
Both homo- and hetero-dimerization of cannabinoid receptor subtypes has previously 
been reported (58). In relation to the current studies, the observation of interactions between 
the CB1 and dopamine D2 receptor (59) may also have relevance to the actions of 
therapeutically-used medicines. Interestingly, co-expression of these two GPCRs was 
reported to alter G protein-coupling selectivity (59) and similar effects have also been 
reported following co-expression of the dopamine D1 and D2 receptors (43). Alteration of G 
protein selectivity via GPCR hetero-dimerization may be an emerging theme in this area and 
hence provide mechanisms to further control signal strength and selectivity.  
The concept that GPCR hetero-dimers may provide novel and selective therapeutic 
targets is still developing (16-17), however, the idea that a range of ligands may modulate 
GPCRs at which they have been considered to have no affinity due to hetero-dimerization 
offers a further novel scenario.  
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FIGURE LEGENDS  
Fig. 1 Doxycycline-dependent cell surface expression of an orexin-1 receptor construct  
(a) Flp-In T-REx HEK293 cells with a VSV-G-h-orexin-1-eYFP construct at the Flp-In locus 
were imaged without (i) and following (ii) doxycycline (1 mg/ml, 72 h) treatment.  
(b) Doxycycline-induced cells were labelled with 1 mM Hoechst 33342 nuclear stain (blue) 
(i-iii) and the plasma membrane marker WGA-Alexa Fluor 594 (red) (ii). Overlay of images 
i and ii (iii) showed co-localization of eYFP and WGA-Alexa Fluor 594. This was 
quantitated on a pixel by pixel basis (right hand side).  
(c) Cell surface anti-VSV-G ELISA confirmed appearance of the VSV-G epitope tag on the 
extracellular surface following doxycycline treatment only of cells harbouring VSV-G-h-
orexin-1-eYFP at the Flp-In locus and not of parental Flp-In T-REx HEK293 cells.  
(d) The time course of expression of VSV-G-h-orexin-1-eYFP in response to treatment with 
doxycycline (1 mg/ml) was monitored following resolution of cell membrane preparations by 
SDS-PAGE and immunoblotting with anti-VSV-G.  
Fig. 2 Orexin A causes phosphorylation of ERK MAP kinases via VSV-G-h-orexin-1-
eYFP and internalization of this construct: SB-674042 is an orexin-1 receptor 
antagonist  
(a, b) Cells harbouring VSV-G-h-orexin-1-eYFP at the Flp-In locus were treated with (+) or 
without (-) doxycycline as in Figure 1 for 72 h, and then treated with orexin A (0.5 mM) (+ 
OXA) or with vehicle (- OXA) for 5 min. Cell lysates were resolved by SDS-PAGE and 
immunoblotted to detect phospho- ERK1/ERK2 (a) or total levels of ERK1/ERK2 (b).  
(c) Cells induced to express VSV-G-h-orexin-1-eYFP were treated with vehicle (CONTROL) 
or orexin A (0.5 mM, 30 min) (OXA).  
(d) Cells as in (c) were pre-treated with SB-674042 (5 mM, 3 h), challenged with SB-674042 
(5 mM) or orexin A (1 mM) + SB-674042 (5 mM) for 30 min and then imaged.  
Fig. 3 Co-expression with h-CB1 alters the cellular distribution of VSV-G-h-orexin-1-
eYFP  
(a) Cells harbouring VSV-G-h-orexin-1-eYFP (left hand panel) or harbouring VSV-G-h-
orexin-1-eYFP and constitutively expressing h-CB1 (right hand panel) were induced to 
express VSV-G-h-orexin-1-eYFP by treatment with doxycycline (1 mg/ml, 72 h). The 
distribution of VSV-G-h-orexin-1-eYFP was then imaged. (b) The specific binding of 
[3H]SR-141716A (5 nM) was measured in membrane preparations of parental Flp-In T-REx 
HEK293 cells, and in Flp-In T-Rex cells induced to express VSV-G-h-orexin-1-eYFP in the 
absence and presence of constitutive expression of the h-CB1 receptor.  
Fig. 4 In the presence of the h-CB1 receptor, VSV-G-h-orexin-1-eYFP adopts the 
cellular location of h-CB1: this reflects hetero-dimerization/oligomerization  
Cells harbouring VSV-G-h-orexin-1-eYFP and constitutively expressing h-CB1-CFP were 
employed. (a) Images were taken corresponding to eYFP and CFP without (i-iii) and with 
(iv-vi) induction of VSV-G-h-orexin-1-eYFP expression for 72 h. (b) Single cell images for 
VSV-G-h-orexin-1-eYFP (i) and h-CB1-CFP (ii) were overlayed (iii) and colour overlap 
determined on a pixel by pixel basis (iv). (c) Direct images and corrected CFP to YFP FRET 
(cFRET) images were recorded after individual expression of VSV-G-h-orexin-1-eYFP 
(upper panels) and h-CB1-CFP (middle panels) or their co-expression (lower panels). 
Quantified cFRET values are detailed.  
Fig. 5 m-opioid receptor distribution is unaffected by the presence of the h-CB1 
receptor  
Flp-In T-REx HEK293 cells with h-CB1-CFP (blue) at the inducible Flp-In locus and 
constitutively expressing h-m-opioid receptor-YFP (yellow) were established and imaged 
both without (a) and with (b) doxycycline-induced (1 mg/ml, 24h) expression of h-CB1-CFP. 
In both situations the YFP signal was predominantly at the cell surface.  
Fig. 6 SR-141716A and SB-674042 are highly selective pharmacological reagents  
(a) The specific binding of [3H]SR-141716A (5 nM) in the absence or presence of orexin A 
(0.5 mM) or SB-674042 (5 mM) was assessed in membranes of cells constitutively 
expressing h-CB-1 without induction of VSV-G-h-orexin-1-eYFP.  
(b) SR-141716A (1 mM, 3 h) was unable to internalize VSV-G-h-orexin-1-eYFP (i) or to 
antagonize orexin A (0.5 mM, 30 min) mediated internalization of this construct in cells 
induced to express VSV-G-h-orexin-1-eYFP in the absence of h-CB-1 (ii).  
(c) The specific binding of [3H]SB-674042 (5 nM) in the absence or presence of SR-141716A 
(1mM) was assessed membranes of cells expressing only VSV-G-h-orexin-1-eYF as in (b).  
Fig. 7 SR-141716A but not SB-674042 relocates h-CB1-CFP to the cell surface  
Cells harbouring, but not induced to express VSV-G-h-orexin-1-eYFP and constitutively 
expressing h-CB1-CFP were untreated (left hand panels) or treated with either SR-141716A 
(1 mM, 3 h) (middle panels) or SB-674042 (5 mM, 3h) (right hand panels). Cells were 
subsequently imaged to detect YFP (top panels), CFP (centre panels) and the YFP and CFP 
images merged (bottom panels). Quantitative analysis is provided in Table 3.  
Fig. 8 SR-141716A and SB-674042 relocate hetero-dimers of orexin-1-eYFP and CB1-
CFP receptors to the cell surface when the two receptors are co-expressed  
a. Cells harbouring VSV-G-h-orexin-1-eYFP and constitutively expressing h-CB1-CFP were 
treated with doxycycline (1 mg/ml, 72 h) to induce VSV-G-h-orexin-1-eYFP expression. The 
cells were untreated (left hand panels) or treated with either SR-141716A (1 mM, 3 h) 
(middle panels) or SB-674042 (5 mM, 3h) (right hand panels). Cells were subsequently 
imaged to detect eYFP (top panels), CFP (bottom panels). Quantitative analysis is provided 
in Table 3.  
b. Direct images and corrected CFP to YFP FRET (cFRET) images were recorded after 
individual expression of h-CB1-CFP (upper panels), VSV-G-h-orexin-1-eYFP (middle 
panels) or their co-expression (lower panels) and treatment with SR-141716A (1 mM, 3 h). 
Quantified cFRET values are detailed. Data represent means +/- S.E.M. for 6 individual cells.  
Fig. 9 SR-141716A decreases the potency of orexin A to stimulate ERK MAP kinase 
phosphorylation via the orexin-1 receptor only when the CB1 receptor is co-expressed  
The ability of varying concentrations of orexin A to cause phosphorylation of the MAP 
kinases ERK1 and ERK2 (top panels) was assessed in Flp-In T-REx HEK293 cells induced 
to express VSV-G-h-orexin-1-eYFP without (a, b) and with (c, d) constitutive expression of 
h-CB1. Cells were pre-treated with (b, d) or without (a, c) SR-141716A (1 mM, 3 h) prior to 
performing the ERK MAP kinase assay. Total ERK1 and ERK2 amounts (bottom panels) 
provided loading controls.  
a. Quantitation of data akin to Figure 8 a-d, means +/- SEM, n = 4.  
TABLES  
Table 1. Cellular distribution of VSV-G-h-orexin-1-eYFP after induction in the absence 
and presence of h-CB1 receptor  
 VSV-G-OX1-YFP  
VSV-G-OX1-YFP  
+ h-CB1  
Cell surface  88.6 +/- 3.6  47.2 +/ 2.6  
Intracellular  11.4 +/- 3.6  52.8 +/- 2.6  
The distribution of VSV-G-h-orexin-1- eYFP between the cell surface and intracellular 
compartments was assessed in Flp-In T-REx HEK293 cells following induction of expression 
by treatment with doxycycline (1 mg/ml, 72 h) in the absence or presence of constitutive 
expression of h-CB1. Data are means +/- S.E.M. from n = 6 individual cells.Table 2. 
Expression levels of cannabinoid CB1 receptor constructs  
 
CB1 + OX1-YFP  
(- Dox)  
CB1 + OX1-YFP 
(+ Dox)  
CB1-CFP + OX1-
YFP  
(- Dox)  
CB1-CFP + OX1-
YFP  
(+ Dox)  
Bmax  
(pmol/mg)  
2.83 +/- 0.11  2.97 +/- 0.06  1.60 +/- 0.08  1.60 +/- 0.52  
Kd (nM)  0.73 +/- 0.10  0.88 +/- 0.26  0.97 +/- 0.13  1.06 +/- 0.01  
Saturation binding studies were performed on membrane preparations of Flp-In T-REx 
HEK293 that constitutively express either h-CB1 or h-CB1-CFP using varying concentrations 
of [3H]SR-141716A. Expression of VSV-G-h-orexin-1-eYFP was produced from the Flp-In 
locus by treatment with doxycycline (+ Dox) as in Table 1.  
Table 3. Effects of SR-141716A and SB-674042 treatment on the cellular distribution of 
orexin-1 and cannabinoid CB1 receptors  
CB1-CFP VSV-G-OX-1-YFP  
+ CB1-CFP  
 Control  
SR-141716A 
(1 mM, 3 h) 
SB-674042 
(5 mM, 3 
h)  
Control  
SR-141716A  
(1 mM, 3 h)  
SB-
674042  
(5 mM, 3 
h)  
Cell surface  
YFP 
intensity  
(OX-1)  
Not 
expressed  
Not  
expressed  
Not  
expressed 
33.9 +/- 
3.1  
81.6 +/- 
4.2  
p < 0.001  
81.7 +/- 3.3  
p < 0.001  
Intracellular Not  Not  Not  66.1 +/- 
3.1  
18.4 +/- 4.2  18.3 +/- 
YFP 
intensity  
(OX-1)  
expressed  expressed  expressed p < 0.001  3.3  
p < 0.001 
Cell surface  
CFP 
intensity  
(CB1)  
8.8 +/-2.0  
54.4 +/- 11.1 
p < 0.01  
6.3 +/- 1.4 8.6 +/- 1.6 
42.2 +/- 5.2  
p < 0.001  
34.3 +/- 
3.9  
p < 0.001 
Intracellular 
CFP 
intensity  
(CB1)  
91.2 +/-2.0  
45.6 +/- 11.1 
p < 0.01  
93.7 +/- 1.4 91.4 +/- 1.6  
57.8 +/- 5.2  
p < 0.001  
65.7 +/- 
3.9  
p < 0.001 
The distribution of VSV-G-orexin-1-h-eYFP and hCB1-CFP between the cell surface and 
intracellular compartments was assessed in Flp-In T-REx HEK293 cells constitutively 
expressing hCB1-CFP in the absence or presence of VSV-G-h-orexin-1-eYFP. Cells were 
untreated (Control) or pre-treated with either SR-141716A or SB-674042 for 3 h. Data are 
means +/- S.E.M. from n = 6 individual cells.Table 4. The potency of orexin A to 
phosphorylate ERK1/ERK2 is decreased by SR-141716A /rimonabant only when the h-
CB1 receptor is co-expressed with the orexin-1 receptor  
 OX1-YFP  
OX1-YFP  
(+ SR-141716A) 
CB1-CFP + OX1-
YFP  
CB1-CFP + OX1-
YFP  
(+ SR-141716A)  
EC50  
Orexin A 
(nM)  
39.4 +/- 4.9  
48.2 +/- 4.9  
NS  
23.0 +/- 1.6  
p = 0.027  
177.3 +/- 12.0  
p = < 0.0001  
The ability of varying concentrations of orexin A to stimulate phosphorylation of the MAP 
kinases ERK1 and ERK2 was quantitated in untreated cells and in those pre-treated with SR-
141716A (1 mM, 3 h). Statistical differences in values are against untreated cells expressing 
VSV-G-h-orexin-1-eYFP. Data are mean +/- S.E.M. n = 4. NS = not significant.  
These studies were performed by immunoblotting with a phospho-specific antibody to detect 
phosphorylated forms of ERK1 and ERK2. Phosphorylation of these kinases is considered 
synonomous with their state of activation. However, no attempt was made to ascertain the 
fraction of total cellular ERK1 and ERK2 that became phosphorylated in response to orexin-
A. Similar caveats apply to the data of Tables 5 and 6.  
Table 5 . The potency of WIN 55, 212-2 to phosphorylate ERK1/ERK2 is decreased by 
SB-674042 only when the h-CB1 receptor is co-expressed with the orexin-1 receptor  
 CB1-CFP  
CB1-CFP  
(+ SB-674042) 
CB1-CFP + OX1-
YFP  
CB1-CFP + OX1-
YFP  
(+ SB-674042)  
EC50  
WIN 55, 212-2 
(nM)  
135.5 +/- 
18.2  
153.0 +/- 15.1  
NS  
144.3 +/- 7.5  
NS  
269.5 +/- 34.0  
p = < 0.05  
The ability of varying concentrations of the cannabinoid CB1 receptor agonist WIN 55, 212-2 
to stimulate phosphorylation of the MAP kinases ERK1 and ERK2 in untreated cells and in 
those pre-treated with SB-674042 (5 mM, 3 h) was quantitated. Statistical differences in 
values are against untreated cells expressing CB1-CFP. Data are mean +/- S.E.M. n = 4. NS = 
not significant.  
Table 6. Co-expression of the h-CB1 receptor and treatment with SR-141716A 
/rimonabant alters the potency of orexin A to phosphorylate ERK1/ERK2 over a wide 
range of orexin-1 receptor expression levels  
 OX1-YFP  OX1-YFP + CB1  
OX1-YFP + CB1  
(+ SR-141716A)  
EC50 Orexin A (nM)  
(1.0 ¼g/ml Dox)  
47.7 +/- 4.3  
25.7 +/- 2.8  
p = 0.0019  
117.0 +/- 27.0  
p = 0.0044  
EC50 Orexin A (nM)  
(0.0001 ¼g/ml Dox)  
92.0 +/- 4.5  
P = 0.0003  
24.3 +/- 3.6  
p = < 0.0001  
NS  
173.7 +/- 37.4  
p = 0.0021  
NS  
EC50 Orexin A (nM)  
(0.0000025 ¼g/ml Dox)  
149.0 +/- 49.0  
= 0.024  
54.3 +/- 1.9  
p = 0.029  
P = < 0.0001  
214.3 +/- 6.6  
p = < 0.0001  
P = 0.0038  
The ability of varying concentrations of orexin A to stimulate phosphorylation of the MAP 
kinases ERK1 and ERK2 was quantitated in Flp-In T-REx HEK293 cells either lacking 
expression of h-CB1-CFP or constitutively expressing h-CB1-CFP. In each case the cells 
harbored VSV-G-h-orexin-1-eYFP at the Flp-In locus and were treated with different 
concentrations of doxycycline to induce expression of VSV-G-h-orexin-1-eYFP. [3H]SB-
674042 binding studies indicated VSV-G-h-orexin-1-eYFP expression to varying 100 fold 
between cells treated with 0.0000025 mg/ml and 1 mg/ml doxycycline. Cells co-expressing 
VSV-G-h-orexin-1-eYFP and h-CB1-CFP were treated with or without SR-141716A (1 mM, 
3 h).  
Statistical differences in values are against untreated cells expressing VSV-G-orexin-1-eYFP 
(p), against untreated VSV-G-orexin-1-eYFP cannibanoid-1 co-expressing cells (p) and 
against cells expressing receptor following induction with 1.0 ¼g/ml doxycycline for each 
cell line independently including cells pre-treated with SR-141716A (P). Data are mean +/- 
S.E.M. n = 3. NS = not significant.  
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